Pubfacts - Scientific Publication Data
  • Categories
  • |
  • Journals
  • |
  • Authors
  • Login
  • Categories
  • Journals

Search Our Scientific Publications & Authors

Publications
  • Publications
  • Authors
find publications by category +
Translate page:

Dismal outcome of T-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry.

Authors:
Irene Biasoli Marina Cesaretti Monica Bellei Antonino Maiorana Goretta Bonacorsi Micol Quaresima Massimiliano Salati Massimo Federico Stefano Luminari

Hematol Oncol 2015 Sep 29;33(3):147-51. Epub 2014 Apr 29.

Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Università di Modena e Reggio Emilia, Modena, Italy.

We conducted a population-based study to establish the outcome of T-cell lymphoma (TCL) patients failing systemic first-line therapy. All TCL patients failing first-line systemic therapy in the province of Modena were identified from Modena Cancer Registry between 1997 and 2010. A total of 53 patients were analysed. Regarding the type of failure, 18 patients relapsed, and 35 progressed during first treatment. Among relapsed patients, the median time from date of response to relapse after first treatment was 6.2 months (range 1.87-102). A total of 18 patients (34%) died before receiving salvage treatment, 21 received platinum or gemcitabine-containing regimens (7 addressed to autologous stem cell transplant (ASCT)), 12 other CT regimens; 2 received radiotherapy (RT). The median survival after relapse (SAR) was 2.5 months. After a median follow-up for living patients after failure of 35 months (range 8-111 months), 44 patients died, and the cause of death was found to be lymphoma progression in all (98%) but one of them. The median SAR was 2.5 months. The 3-year SAR was 19%. Univariate and multivariate Cox regression analyses for SAR were performed. In multivariate analysis, performance status and type of failure were associated with a higher risk of death after relapse. The outcome of TCL patients failing first-line therapy is poor. Only a few cases that could receive ASCT had promising chances of long remission. There is urgent need for novel agents for patients requiring second-line treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1002/hon.2144DOI Listing
September 2015

Publication Analysis

Top Keywords

patients failing
16
tcl patients
12
failing first-line
12
patients
11
months range
8
sar months
8
cancer registry
8
modena cancer
8
outcome t-cell
8
first-line therapy
8
t-cell lymphoma
8
population-based study
8
total patients
8
type failure
8
months
5
treatment
5
receive asct
4
cell transplant
4
transplant asct
4
stem cell
4

Keyword Occurance

Similar Publications

High prevalence of NRTI and NNRTI drug resistance among ART-experienced, hospitalized inpatients.

Authors:
Claire Bossard Birgit Schramm Stephen Wanjala Lakshmi Jain Gisele Mucinya Valarie Opollo Lubbe Wiesner Gilles Van Cutsem Elisabeth Poulet Elisabeth Szumilin Tom Ellman David Maman

J Acquir Immune Defic Syndr 2021 Apr 1. Epub 2021 Apr 1.

Epicentre, Médecins sans Frontières, Paris, France OCP, Médecins sans Frontières, Nairobi, Kenya OCP, Médecins sans Frontières, Homa Bay, Kenya OCB, Médecins sans Frontières, Kinshasa, DRC Kenya Medical Research Institute/Centre for Global Health Research, Kisumu, Kenya Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa Southern African Medical Unit, Médecins sans Frontières, Cape Town, South Africa Centre for Infectious Disease Epidemiology and Research, University of Cape Town, South Africa OCP, Médecins sans Frontières, Paris, France.

Background: Patients hospitalized with advanced HIV have a high mortality risk. We assessed viremia and drug resistance amongst differentiated care services and explored whether expediting the switching of failing treatments may be justified.

Setting: Hospitals in the Democratic Republic of Congo (HIV hospital), and Kenya (general hospital including HIV care). Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Successful treatment of epilepsia partialis continua with perampanel: two pediatric cases.

Authors:
Ali Mir Montaha Almudhry Fouad Al-Ghamdi Shahid Bashir

Epileptic Disord 2021 Apr 12. Epub 2021 Apr 12.

Department of Pediatric Neurology, King Fahad Specialist Hospital, Dammam, Saudi Arabia.

Epilepsia partialis continua (EPC) is a form of focal motor status epilepticus, associated with multiple etiologies. Etiology-specific treatments, such as hemispherotomy for Rasmussen encephalitis, lesionectomy for focal cortical dysplasia, and metabolic correction for non-ketotic hyperglycemia, have proven to be efficacious in treating EPC, but, in general, EPC is difficult to treat and often drug-resistant, and there is little evidence to guide therapy. We report the successful treatment of EPC with perampanel in two pediatric patients. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Cell-Based Therapies for Age-Related Macular Degeneration.

Authors:
Samer Khateb Shekhar Jha Kapil Bharti Eyal Banin

Adv Exp Med Biol 2021 ;1256:265-293

Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Age-related macular degeneration (AMD) is a leading cause of blindness worldwide. The pathogenesis of AMD involves dysfunction and loss of the retinal pigment epithelium (RPE), a monolayer of cells that provide nourishment and functional support for the overlying photoreceptors. RPE cells in mammals are not known to divide, renew or regenerate in vivo, and in advanced AMD, RPE loss leads to degeneration of the photoreceptors and impairment of vision. Read More

View Article and Full-Text PDF
January 2021
Similar Publications

Free from Dysphagia? A Test Battery to Differentiate Between Mild and No Dysphagia.

Authors:
Emma Lindroos Kerstin Johansson

Dysphagia 2021 Apr 12. Epub 2021 Apr 12.

Department of Speech and Language Pathology, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.

Assessing mild oropharyngeal dysphagia (OD) raises the question where to draw the line between normal and pathological swallowing. There is a lack of clinical test methods appropriate in the subacute phase of recovery from dysphagia following stroke and other brain injuries. The aim of this pilot study was to investigate the diagnostic accuracy of a new test battery, called the Swallow Battery (SwaB), in relation to Fiberoptic Endoscopic Evaluation of Swallowing (FEES). Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: a multicenter series of 32 consecutive cases.

Authors:
Naseema Gangat Paola Guglielmelli Natasha Szuber Kebede H Begna Mrinal M Patnaik Mark R Litzow Aref Al-Kali James M Foran Jeanne M Palmer Hassan Alkhateeb Michelle A Elliott Curtis A Hanson Animesh Pardanani Francesco Mannelli Alessandro M Vannucchi Ayalew Tefferi

Am J Hematol 2021 Apr 12. Epub 2021 Apr 12.

Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an effective treatment regimen for acute myeloid leukemia, in both de novo and relapsed/refractory setting. The current multicenter study retrospectively examined Ven+HMA treatment outcome among 32 patients (median age 69 years; 59% males) with blast-phase myeloproliferative neoplasm (MPN-BP). Pre-leukemic phenotype included essential thrombocythemia (ET)/post-ET myelofibrosis (34%), polycythemia vera (PV)/post-PV myelofibrosis (38%) and primary myelofibrosis (28%). Read More

View Article and Full-Text PDF
April 2021
Similar Publications
© 2021 PubFacts.
  • About PubFacts
  • Privacy Policy
  • Sitemap